Cellectis (CLLS) Cost of Revenue (2015 - 2023)

Cellectis' Cost of Revenue history runs 9 years deep, the most recent figure standing at -$344000.0 for Q4 2023.

• On a quarterly basis, Cost of Revenue fell 149.86% year-over-year to -$344000.0 in Q4 2023; TTM through Dec 2023 was $412000.0, a 76.74% decrease from a year earlier, with the FY2023 full-year figure at $737000.0, down 58.41% from the prior year.
• Cost of Revenue fell to -$344000.0 in Q4 2023 per CLLS's latest filing, from $367000.0 in the prior quarter.
• Across five years, Cost of Revenue topped out at $18.6 million in Q4 2020 and bottomed at -$344000.0 in Q4 2023.
• The 5-year median for Cost of Revenue is $752500.0 (2019), against an average of $4.0 million.
• Across the five-year window, Cost of Revenue jumped 685.0% in 2019 and plunged 149.86% in 2023, its largest moves.
• Year by year, Cost of Revenue stood at $5.7 million in 2019, then jumped by 229.87% to $18.6 million in 2020, then slumped by 98.7% to $243000.0 in 2021, then jumped by 183.95% to $690000.0 in 2022, then plunged by 149.86% to -$344000.0 in 2023.
• Per Business Quant, the three latest CLLS Cost of Revenue figures stand at -$344000.0 (Q4 2023), $367000.0 (Q3 2023), and $55000.0 (Q2 2023).